Here are Siltanen’s comments regarding the recent news above. 
Aiforia announced on Thursday that it has been selected as the AI partner for the French PROSTIA project. With the agreement, the company’s prostate cancer diagnostic solution will be implemented in five new Assistance Publique–Hôpitaux de Paris (AP-HP) pathology sites, in addition to the previous two. In our assessment, the two-year project includes the possibility of long-term use of Aiforia’s solutions in these hospitals, both for prostate cancer and potentially for other use cases later on. The announcement supports our growth forecasts for the coming years.